Welcome to our dedicated page for Exact Sciences SEC filings (Ticker: EXAS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Phase III trial data, FDA comment letters, and dense genomic terminology can make Exact Sciences’ disclosures feel like a scientific journal rather than an SEC filing. If you have ever hunted for one sentence on Cologuard reimbursement or tried to tally option grants across multiple exhibits, you know the challenge.
Stock Titan solves that problem. Our AI reads every Exact Sciences quarterly earnings report 10-Q filing, annual report 10-K simplified, and even late-night 8-K material events explained, highlighting trial milestones, cash-burn trends, and partnership revenue so you don’t have to. Interactive dashboards surface Exact Sciences Form 4 insider transactions real-time, while concise summaries translate complex molecular-diagnostic jargon into plain language—perfect for understanding Exact Sciences SEC documents with AI.
Need specifics? Quickly answer questions such as:
- "What drives R&D expense spikes?"—see segment footnotes drawn from the 10-K.
- "Did executives buy shares after the Oncotype DX update?"—check Exact Sciences insider trading Form 4 transactions with timestamped alerts.
- "How will a new CMS coverage decision impact revenue?"—our AI links reimbursement disclosures across 8-Ks.
From Exact Sciences proxy statement executive compensation tables to Exact Sciences earnings report filing analysis, every document arrives within seconds of hitting EDGAR—complete, searchable, and contextualized. Make data-driven calls on pipeline progress, IP strength, and executive conviction without wading through 300 pages of technical detail.
FMR LLC and Abigail P. Johnson report shared beneficial ownership of 18,588,183.06 shares of Exact Sciences Corp common stock, representing 9.8% of the class. FMR LLC is shown with 17,584,537.69 shares of sole voting power and 18,588,183.06 shares of sole dispositive power. The filing states these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. An exhibit is referenced for a related 13d-1(k) agreement.
James Edward Doyle, a director of Exact Sciences Corporation (EXAS), reported a sale of company common stock. The Form 4 shows a disposition of 1,485 shares on 08/13/2025 at a reported price of $42.02 per share under a Rule 10b5-1 trading plan established on 03/09/2025. After the sale, the filing reports 59,962 shares beneficially owned by Mr. Doyle. The Form 4 was signed via power of attorney on 08/14/2025.
Exact Sciences (EXAS) submitted a Form 144 notifying a proposed sale of 1,485 shares of common stock through Fidelity Brokerage Services LLC (900 Salem Street, Smithfield, RI 02917) with an aggregate market value of $62,399.70. The securities were acquired on 06/12/2025 by restricted stock vesting and payment is listed as compensation. The approximate date of sale is reported as 08/13/2025, and the filing states there were no securities sold during the past three months by the person for whose account the sale is proposed. The filing also discloses total shares outstanding of 189,319,110 and includes the standard representation that the filer does not know of any undisclosed material adverse information.
FAQ
What is the current stock price of Exact Sciences (EXAS)?
What is the market cap of Exact Sciences (EXAS)?
